Leadership

Richard A. Miller, M.D.

President and CEO, Co-Founder

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude. He is a board-certified oncologist and was Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center until 2023.

Leiv Lea

Chief Financial Officer

Mr. Lea served as the Chief Financial Officer of Pharmacyclics from 1998 to 2008. He received a B.S. in agricultural economics from the University of California, Davis, and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Jeffrey Arcara

Chief Business Officer

Jeffrey Arcara joined Corvus in 2024 as Chief Business Officer to lead the company’s corporate strategy, business development, portfolio strategy, and new product planning. With over 30 years of commercial expertise in the biopharmacuetical industry, Mr. Arcara has broad functional experience across a range of large and small biopharma companies. He previously served as senior vice president, head global marketing & portfolio and strategy for the specialty and biosimilars business at Teva Pharmaceuticals where he held commercial leadership roles of increasing responsibility across several different disease areas. Mr. Arcara holds an MBA from the UCLA Anderson School of Management and a B.A. in Finance and Marketing from University of Wisconsin-Madison.

William Ben Jones, Ph.D.

Senior Vice President, Pharmaceutical Developmentr

Dr. Jones was Director of Global Regulatory Affairs in Sanofi U.S.’s oncology business unit from December 2012 to December 2014. From 2008 to March 2012, he was Director of Project Management & Regulatory at Pharmacyclics, where he played a principal role in the development of ibrutinib. Prior to Pharmacyclics, he was Associate Director of Development at Plexxikon and Senior Project Manager at Vertex Pharmaceuticals. Dr. Jones earned a B.S. and a Ph.D. in chemistry from the University of Cincinnati and completed a post-doctoral fellowship at the University of Oxford.

Otute Akiti, PhD

Vice President, CMC

Dr. Akiti joined Corvus in 2024 as Vice President of CMC. Prior to joining Corvus he was at Neumora Therapeutics, where he built and scaled the Technical Operations team, supporting assets from preclinical to late-stage development, while establishing a robust and agile supply chain network.

Prior to this, he served in leadership roles at BlackThorn Therapeutics and Relypsa, where he managed cross-functional teams to deliver critical milestones, including the launch of Veltassa. Earlier in his career, he held key technical and leadership positions at Exelixis and Bristol-Myers Squibb, contributing to the development of approved therapies like Cometriq.

Dr Akiti has deep expertise in process development, quality systems, and regulatory strategy, with significant experience successfully navigating FDA and EMA regulatory pathways. A respected leader in the pharmaceutical industry, he has held key roles with professional organizations, including serving as president and executive member of the North American Mixing Forum and as a session chair for numerous AIChE conferences.

Dr. Akiti earned a Ph.D. in Chemical Engineering from the New Jersey Institute of Technology, an M.S. in Chemical Engineering from Northeastern University, and a B.S. in Chemical Engineering from the University of California, Berkeley.

Bill DeVincenzi

Vice President, Quality Assurance

Mr. DeVincenzi joined Corvus Pharmaceuticals in 2026 as Vice President, Quality Assurance. He brings more than 30 years of biopharmaceutical industry experience in quality assurance. Prior to joining Corvus, he served as Vice President, Head of Quality at Engrail Therapeutics, and Vice President, Quality at Acer Therapeutics (acquired by Zevra Therapeutics). Earlier, he held senior quality leadership roles at Zogenix, Sunesis Pharmaceuticals, Hana Biosciences, CoTherix (acquired by Actelion) and Depomed. Mr. DeVincenzi earned a Master’s of Business Administration from San Jose State University and a B.S. in Genetics from the University of California, Davis.

Zack Kubow

Vice President, Investor Relations and Corporate Communications

Mr. Kubow joined Corvus in 2026 as Vice President, Investor Relations and Corporate Communications. He brings more than 20 years of experience in healthcare industry communications. Prior to joining Corvus, he led the investor relations practice at Real Chemistry, a global healthcare communications network, where he also served as a leader across the corporate affairs, sustainability and biotechnology teams. Prior to this, he served as senior leader at The Ruth Group, a boutique investor relations and public relations agency serving the healthcare industry. Mr. Kubow earned a B.S. in Molecular Environmental Biology from the University of California, Berkeley.

Patrick Leong, PhD

Vice President, Head of Regulatory Affairs

Dr. Leong joined Corvus in 2026 as Vice President, Head of Regulatory Affairs. He brings more than 20 years of experience in regulatory affairs in the biopharmaceutical industry. Prior to joining Corvus, he was Vice President, Head of Regulatory Affairs, Oncology at Ascendis Pharma. Prior to this, he held roles of increasing responsibility in regulatory affairs at Genentech. He began his career in industry on the regulatory affairs teams at Elan Pharmaceuticals and Amgen.

Dr. Leong earned a Ph.D. in Membrane Transport Physiology and Master of Science in Regulatory Science from the University of Southern California. He earned a Master of Science in Pharmaceutical Sciences from University of Florida.

Gabriel Luciano

Vice President Clinical Operations

Mr. Luciano joined Corvus in 2018 and has served as Vice President of Clinical Operations since 2021. He was Senior Director of Clinical Operations at Pharmacyclics from 2012 to 2017 where he played a principal role in the initial clinical development and initial marketing approvals for ibrutinib. From 2008 to 2011, he was Senior Clinical Trial Manager at Seattle Genetics where he supported the initial clinical trial development and initial marketing approvals for brentuximab vedotin. From 1990 to 2008 he held various Clinical Operations positions at Abgenix, Pharmacyclics, Quintiles, Covance and Syntex. Mr. Luciano earned a B.A. in Psychology and Biology from the University of California at Santa Cruz.

Suresh Mahabhashyam, M.D., MPH

Vice President Clinical Development

Dr. Mahabhashyam joined Corvus in 2019 and has served as its Vice President of Clinical Development since 2020. He was Vice President Drug Safety at Infinity Pharmaceuticals from 2016 to 2019. Prior to Infinity, he was Senior Medical Director at Alexion from 2012 to 2015. Dr. Mahabhashyam earned his medical degree from Bangalore Medical College and his MPH in epidemiology from University of North Texas Health Science Center.

Nick Topoian

Vice President, Controller

Mr. Topoian joined Corvus Pharmaceuticals in 2017 and has served as Vice President, Controller since 2023. He brings more than 20 years of experience in the biopharmaceutical industry, spanning corporate finance, controllership, and financial planning and analysis. Prior to joining Corvus, he served in finance and accounting roles of increasing responsibility at Versartis, Pharmacyclics and Gilead. He began his career in Deloitte's audit practice, serving publicly traded and emerging growth companies. Mr. Topoian earned a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley.

Andrew Chan, M.D., Ph.D.

Dr. Chan is a physician-scientist with extensive leadership experience in industry and academic medicine. He joined Genentech in 2001 and spent more than two decades with the company, most recently serving as Senior Vice President, Research Biology from 2010 to 2025. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology.

Dr. Chan has also held longstanding academic and clinical roles at the University of California, San Francisco (UCSF). He has served as an Associate Adjunct Professor of Medicine in the Division of Rheumatology since 2020 and practiced as an attending physician at UCSF Long-Moffitt Hospital and Barnes Hospital.

Prior to UCSF, he was an Associate Professor of Medicine at Washington University School of Medicine and an Associate Investigator of the Howard Hughes Medical Institute.

Dr. Chan earned his B.A. and M.S. in Chemistry from Northwestern University and his M.D. and Ph.D. from Washington University School of Medicine.

Linda S. Grais, M.D., J.D.

Dr. Grais was president and chief executive officer of Ocera Therapeutics, Inc., a biopharma company developing new treatments for serious liver disease, until its acquisition by Mallinckrodt. Prior to that, she was a partner at InterWest Partners, a venture capital firm focused on biotechnology and medical device companies. Previously, Dr. Grais was a founder and executive vice president of Structural GenomiX, Inc., a drug discovery company focusing on new treatments for cancer that was acquired by Eli Lilly & Co. Earlier in her career, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented life science companies in venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais currently serves on the board of directors of Arca Biopharma, Inc., ICON plc and Collective Health, a private healthcare services company. Dr. Grais received a B.A. in philosophy from Yale University, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.

Richard A Miller, M.D.

CHAIRMAN and CO-FOUNDER

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

David Moore

Mr. Moore previously served as Executive Vice President, US Operations, and President at Novo Nordisk Inc., the US subsidiary of Novo Nordisk A/S. He held positions of increasing responsibility at Novo Nordisk, including Executive Vice President, Corporate Development and Senior Vice President, Commercial at Novo Nordisk, Inc. Mr. Moore’s other experience also includes serving as an investment partner at Gurnet Point Capital, a life science focused private equity firm; chief executive officer of Lysovant Sciences, a Roivant company; and president and chief commercial officer of Cempra Pharmaceuticals. Mr. Moore began his career at Johnson & Johnson, where he spent 14 years in roles of increasing responsibility across sales, marketing and business development. Mr. Moore holds an MBA in Marketing from Lehigh University and a Bachelor of Science in Biology from Towson University.

Peter Thompson, M.D.

CO-FOUNDER

Dr. Thompson is currently a Member at OrbiMed Advisors LLC and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.

Richard A. van den Broek

Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and has served as a director of Pulse Biosciences, Inc since 2020. Mr. van den Broek previously served on the board of directors of Pharmacyclics, Inc. from December 2009 through its acquisition by AbbVie, announced in March 2015. Mr. van den Broek received an A.B. degree from Harvard University and is a Chartered Financial Analyst.